GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyper Corporation Inc (XKRX:065650) » Definitions » Common Stock

Hyper (XKRX:065650) Common Stock : ₩31,577 Mil (As of Mar. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Hyper Common Stock?

Hyper's quarterly common stock stayed the same from Sep. 2023 (₩25,871 Mil) to Dec. 2023 (₩25,871 Mil) but then increased from Dec. 2023 (₩25,871 Mil) to Mar. 2024 (₩31,577 Mil).

Hyper's annual common stock increased from Dec. 2021 (₩21,808 Mil) to Dec. 2022 (₩23,522 Mil) and increased from Dec. 2022 (₩23,522 Mil) to Dec. 2023 (₩25,871 Mil).


Hyper Common Stock Historical Data

The historical data trend for Hyper's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyper Common Stock Chart

Hyper Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14,719.56 18,599.94 21,807.98 23,521.78 25,871.48

Hyper Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23,521.78 23,748.20 25,871.48 25,871.48 31,576.64

Hyper Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Hyper (XKRX:065650) Business Description

Traded in Other Exchanges
N/A
Address
Woolim A-1401, 583, Yangcheon-ro, Gangseo-gu, Seoul, KOR, 07547
Medifron DBT Co Ltd is a Korean clinical stage biopharmaceutical company. The company is focused on the development of Alzheimer's disease (AD) and neuropathic pain (NP) treatment and AD diagnostics.

Hyper (XKRX:065650) Headlines

No Headlines